US firm Warner-Lambert's German drugmaking business, comprising ofGoedecke and Parke-Davis, is reaping the benefits of its decision to concentrate European drug production in two sites, one at Freiburg, Germany, and the other in Orleans, France. The two companies together posted a 5.2% rise in 1996 sales to 591 million Deutschemarks ($327 million), which constitutes Warner-Lambert's second-largest overseas drug production operation.
Impressive Production Growth Production has risen over the past four years from 700 million to 2.6 billion units, and is expected to increase by a further 20% through 1997. The workforce is also expected to grow to 714 by the end of the year, while Goedecke group sales in Germany alone have expanded since 1993 by 27% to 390.5 million marks.
Despite continual growth over the four-year period, total 1996 profits fell 20%, from 84 million marks in the previous year to 67 million marks, which the company claimed reflects continued pressure on prices.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze